Cited 2 times in
Evaluation of a quantitative RT-PCR assay to detect HER2 mRNA overexpression for diagnosis and selection of trastuzumab therapy in breast cancer tissue samples.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김승일 | - |
dc.date.accessioned | 2015-12-28T11:03:36Z | - |
dc.date.available | 2015-12-28T11:03:36Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0014-4800 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/138605 | - |
dc.description.abstract | Breast cancer patients who have a positive result for HER2 overexpression are commonly treated with Herceptin, a HER2-targeted therapy. In the present study, the BrightGen HER2 RT-qDx (Syantra, Calgary, Canada), which is based on a one-tube nested RT-qPCR method that detects HER2 mRNA overexpression, was clinically evaluated in a total of 237 formalin-fixed paraffin-embedded (FFPE) tissue samples from breast cancer patients. Among the 38 HER2 positive samples, which were determined via IHC/FISH methods, 13 samples out of 16 (81.3%) that were IHC2+/FISH+ and 22 samples out of 22 (100%) that were IHC3+ have been decided positive for HER2 expression via the RT-qPCR method. The true positivity and false positivity results for the RT-qPCR were 92% (35/38) and 2% (1/65), respectively. The concordance between RT-qPCR and IHC results and RT-qPCR and IHC/FISH was 87.2% and 92.1%, respectively. Conclusively, the BrightGen HER2 RT-qDx may be a reliable and convenient method that can supplement traditional IHC and FISH methods for efficient use of trastuzumab. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 368~374 | - |
dc.relation.isPartOf | EXPERIMENTAL AND MOLECULAR PATHOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized/therapeutic use | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use | - |
dc.subject.MESH | Breast Neoplasms/diagnosis* | - |
dc.subject.MESH | Breast Neoplasms/drug therapy | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Genes, erbB-2 | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunohistochemistry | - |
dc.subject.MESH | In Situ Hybridization, Fluorescence | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Molecular Targeted Therapy/methods* | - |
dc.subject.MESH | Polymerase Chain Reaction/methods* | - |
dc.subject.MESH | RNA, Messenger/analysis* | - |
dc.subject.MESH | Receptor, ErbB-2/analysis* | - |
dc.subject.MESH | Sensitivity and Specificity | - |
dc.subject.MESH | Trastuzumab | - |
dc.subject.MESH | Young Adult | - |
dc.title | Evaluation of a quantitative RT-PCR assay to detect HER2 mRNA overexpression for diagnosis and selection of trastuzumab therapy in breast cancer tissue samples. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학) | - |
dc.contributor.googleauthor | Hye young Wang | - |
dc.contributor.googleauthor | Sunghyun Kim | - |
dc.contributor.googleauthor | Sangjung Park | - |
dc.contributor.googleauthor | Seungil Kim | - |
dc.contributor.googleauthor | Dongju Jung | - |
dc.contributor.googleauthor | Kwang Hwa Park | - |
dc.contributor.googleauthor | Hyeyoung Lee | - |
dc.identifier.doi | 10.1016/j.yexmp.2014.09.011 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00658 | - |
dc.relation.journalcode | J00861 | - |
dc.identifier.eissn | 1096-0945 | - |
dc.identifier.pmid | 25236569 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S001448001400152X | - |
dc.subject.keyword | Breast cancer | - |
dc.subject.keyword | FFPE tissue | - |
dc.subject.keyword | HER2 | - |
dc.subject.keyword | Herceptin (trastuzumab) | - |
dc.subject.keyword | Molecular diagnosis | - |
dc.subject.keyword | RT-qPCR | - |
dc.contributor.alternativeName | Kim, Seung Il | - |
dc.contributor.affiliatedAuthor | Kim, Seung Il | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 97 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 368 | - |
dc.citation.endPage | 374 | - |
dc.identifier.bibliographicCitation | EXPERIMENTAL AND MOLECULAR PATHOLOGY, Vol.97(3) : 368-374, 2014 | - |
dc.identifier.rimsid | 38438 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.